Experienced in Teratocarcinosarcoma

Dr. David J. Adelstein

Hematology Oncology
9500 Euclid Ave, 
Cleveland, OH 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Teratocarcinosarcoma
9500 Euclid Ave, 
Cleveland, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Adelstein is a Hematologist Oncology provider in Cleveland, Ohio. Dr. Adelstein is rated as an Experienced provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are Laryngeal Cancer, Throat Cancer, Nasopharyngeal Carcinoma, Epithelial-Myoepithelial Carcinoma, and Thyroidectomy.

His clinical research consists of co-authoring 105 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in OH
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO

Locations

9500 Euclid Ave, Cleveland, OH 44195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Cisplatin, Carboplatin
Study Phase: Phase 2
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
View 8 Less Clinical Trials

105 Total Publications

Self-Perceived Hearing Outcomes With Radiation and Cisplatin or Radiation and Cetuximab for Patients With Human Papilloma Virus (HPV)-Positive Oropharyngeal Cancer-Results From NRG Oncology RTOG 1016.
Self-Perceived Hearing Outcomes With Radiation and Cisplatin or Radiation and Cetuximab for Patients With Human Papilloma Virus (HPV)-Positive Oropharyngeal Cancer-Results From NRG Oncology RTOG 1016.
Journal: International journal of radiation oncology, biology, physics
Published: May 02, 2024
Similar Doctors
Experienced in Teratocarcinosarcoma
Dr. Ankit Mangla
Hematology Oncology | Hematology | Oncology
Experienced in Teratocarcinosarcoma
Dr. Ankit Mangla
Hematology Oncology | Hematology | Oncology

University Hospitals Medical Group Inc

11100 Euclid Ave, 
Cleveland, OH 
 (0.8 miles away)
216-844-1000
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Ankit Mangla is a Hematologist Oncology specialist and a Hematologist in Cleveland, Ohio. Dr. Mangla is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are Melanoma, Adult Soft Tissue Sarcoma, Angiosarcoma of the Scalp, and Angiosarcoma. Dr. Mangla is currently accepting new patients.

Experienced in Teratocarcinosarcoma
Dr. Larisa Schwartzman
Hematology Oncology
Experienced in Teratocarcinosarcoma
Dr. Larisa Schwartzman
Hematology Oncology

Avon - Richard E. Jacobs Health Center

33100 Cleveland Clinic Blvd, 
Avon, OH 
 (18.8 miles away)
Languages Spoken:
English
See accepted insurances

Larisa Schwartzman is a Hematologist Oncology provider in Avon, Ohio. Dr. Schwartzman is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. Her top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Childhood Iron Deficiency Anemia.

Experienced in Teratocarcinosarcoma
Dr. Henry B. Koon
Hematology Oncology
Experienced in Teratocarcinosarcoma
Dr. Henry B. Koon
Hematology Oncology
11100 Euclid Avenue, 
Cleveland, OH 
 (0.9 miles away)
216-844-3951
Languages Spoken:
English
See accepted insurances

Henry Koon is a Hematologist Oncology provider in Cleveland, Ohio. Dr. Koon is rated as an Advanced provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are Melanoma, Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, and Merkel Cell Carcinoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Adelstein's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile